Emergent BioSolutions (EBS) Cash from Financing Activities (2010 - 2026)

Emergent BioSolutions' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$11.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 2750.0% year-over-year to -$11.4 million; the TTM figure through Mar 2026 stood at -$147.6 million (up 36.13% YoY), while the FY2025 annual figure was -$136.6 million, up 28.11% from the prior year.
• Cash from Financing Activities was -$11.4 million for Q1 2026 at Emergent BioSolutions, up from -$113.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $353.1 million in Q4 2022 to a low of -$486.9 million in Q2 2023.
• Historically, Cash from Financing Activities has averaged -$23.1 million across 5 years, with a median of -$11.4 million in 2026.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities surged 4686.0% in 2022, then plunged 22880.0% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $353.1 million in 2022, then tumbled by 98.67% to $4.7 million in 2023, then tumbled by 89.36% to $500000.0 in 2024, then slumped by 22880.0% to -$113.9 million in 2025, then jumped by 89.99% to -$11.4 million in 2026.
• The last three Cash from Financing Activities figures came in at -$11.4 million (Q1 2026), -$113.9 million (Q4 2025), and -$15.9 million (Q3 2025), per Business Quant data.